by admin | Nov 9, 2022 | Press Releases
Friday, November 4, 2022 7:00 AM ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company...
by admin | May 25, 2022 | Press Releases
Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB...
by admin | Feb 8, 2021 | Press Releases
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE /...
by admin | Nov 17, 2020 | Uncategorized
ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing...
by admin | Nov 17, 2020 | Uncategorized
Monday, June 15, 2020 3:45 PMENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company...